Neoadjuvant treatment for borderline and resectable pancreatic ductal adenocarcinoma Review uri icon

Overview

MeSH Major

  • Adenocarcinoma
  • Carcinoma, Pancreatic Ductal
  • Neoadjuvant Therapy
  • Pancreatic Neoplasms

abstract

  • Nowadays and given the improvement in response rate with the new schemes of treatment with chemotherapy, the interest in neoadjuvant treatment for pancreatic ductal adenocarcinoma, allowing the early application of systemic therapies, has also increased. However, treatment selection fundamentally depends on decisions taken by multidisciplinary committees due to the absence of randomized trials on this indication and because the available evidence is based primarily on small studies. The present manuscript tries to establish recommendations based on the available evidence and expert opinion to correctly select the indication, the type of treatment, as well as its duration and how to correctly follow-up patients during treatment with chemotherapy.

publication date

  • October 2017

Research

keywords

  • Review

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1007/s12094-017-1680-8

PubMed ID

  • 28612203

Additional Document Info

start page

  • 1193

end page

  • 1198

volume

  • 19

number

  • 10